China Top Phone Maker Vivo Seeks Oversea Sales Growth
China's No.1 smartphone maker Vivo is seeking to grow sales from overseas markets like Southeast Asia as the Chinese market remains competitive. Vivo Chief Operating Officer Hu Baishan told Bloomberg TV's Stephen Engle at the sideline of the Boao Asia forum.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
39 minutes ago
- Business Insider
Tesla's (TSLA) Full Self-Driving Could Expand in China Due to New Data Export Rules
China has released draft guidelines that could help EV maker Tesla (TSLA) expand its advanced driver-assistance features in the country, according to a Bloomberg report on Friday. For the first time, Beijing has provided clear rules on how data generated in China, including from driver-assistance systems and product development, can be accessed, used, and exported. This is an important step for companies like Tesla, which need to send data abroad in order to improve their systems. Confident Investing Starts Here: The proposed guidelines were published by China's Ministry of Industry and Information Technology, along with seven other government agencies, and are now open for public comment. The framework covers key types of information, such as autonomous driving algorithms, training images, operational data, and vehicle-to-road perception data. These are all critical for developing and improving advanced driver-assistance technologies like Tesla's Full Self-Driving (FSD) system. Being able to export this data is especially valuable for Tesla because the core team working on FSD is based in the U.S., and having access to real-world data from Chinese roads would help optimize the system's performance in China, the world's largest car market. It's worth noting that, until now, strict data controls have been a barrier for foreign automakers. However, the new guidelines could provide Tesla with a clearer path to making its most advanced driver-assistance features more competitive in China. What Is the Prediction for Tesla Stock? Overall, analysts have a Hold consensus rating on TSLA stock based on 14 Buys, 12 Holds, and nine Sells assigned in the past three months, as indicated by the graphic below. Furthermore, the average TSLA price target of $285.97 per share implies 12.1% downside risk.
Business Insider
2 hours ago
- Business Insider
Short-Seller Chanos and Michael Saylor Argue Over Strategy Stock's (MSTR) Valuation
The war of words between famous short-seller Jim Chanos and Strategy's (MSTR) executive chairman, Michael Saylor, over the Bitcoin treasury company's premium valuation continues. In an interview with Bloomberg TV, Chanos called Saylor a 'wonderful salesman' and believes that Strategy, previously known as MicroStrategy, should not be valued only on the basis of its Bitcoin Holdings. Confident Investing Starts Here: Notably, Strategy has been accumulating Bitcoin by raising funds through equity or debt offerings to purchase the cryptocurrency. Interestingly, the company has shifted to selling preferred stock to fund its Bitcoin purchases, instead of convertible bonds or at-the-money common stock sales. Chanos Suggests that Traders Short Strategy Stock The debate between Chanos and Saylor was triggered when the former suggested that traders should short Strategy stock and purchase Bitcoin directly. Chanos explained that the premium enjoyed by MSTR stock over the value of Bitcoin holdings could narrow, presenting an opportunity for the arbitrage trade. Chanos thinks that Strategy's market value should not be more than the value of its Bitcoin holdings. For context, as of June 9, the company held 582,000 Bitcoins, worth around $62.3 billion, while MSTR stock's market value of $108 billion was over 1.7 times its crypto holdings. Chanos believes that this disconnect creates an arbitrage opportunity to buy the largest cryptocurrency and short MSTR stock. However, Saylor disagrees with the short seller's trading recommendation, saying, 'I don't think he understands what our business model is.' He highlighted that Strategy is the largest issuer of Bitcoin-backed credit instruments in the world. He added that Chanos still doesn't understand that MSTR is an operating company and not a closed-end trust or a holding company. While trusts can't leverage Bitcoin, issue preferred shares, and/or issue permanent shares, Strategy can do these. Chanos has previously called Saylor's tactics 'financial gibberish.' Saylor cautioned that if MSTR stock trades at a weak premium, the company is going to sell the preferred stock and buyback common shares, and if the stock rallies, Chanos is 'going to get liquidated and wiped out.' Is MSTR Stock a Buy, Sell, or Hold? Unlike Chanos, most Wall Street analysts are bullish on Strategy stock, with a Strong Buy consensus rating based on 12 Buys and one Sell recommendation. In addition, the average MSTR stock price target of $524.92 per share implies 37.1% upside potential.
Yahoo
3 hours ago
- Yahoo
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR)-based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: View original content to download multimedia: SOURCE Gene Solutions Genomics Pte Ltd Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
